Abstract 5537
Background
The clinical potential of many promising anti-tumor drugs is restricted by their intrinsic physicochemical properties and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. To overcome these hurdles, we have developed a new drug delivery system based on polyurea/polyurethane nanocapsules (NCs), which might protect the loaded drug from premature degradation and specifically release it inside cancer cells. Polyurea/polyurethane polymers present amphoteric properties, thus, these NCs are anionic at basic pH and cationic at acid pH. Tumor microenvironment is slightly acidic (6.8-7) in comparison to healthy tissue (7.2-7.4); hence, NCs became cationic in the tumor area, what facilitates their internalization into tumor cells.
Methods
In order to study this novel delivery system, an analog of tambjamine has been loaded in these amphoteric NCs and their selectivity and antitumor properties have been analyzed in vitro comparing two pHs, one acidic (6.8) and another basic (7.5) by proliferation assays, flow cytometry and microscopy. Additionally, the toxicity and efficacy of this delivery approach has been evaluated in an orthotopic lung cancer mouse model.
Results
In vitro results showed higher levels of NCs uptake in tumor cells at pH 6.8, resulting in greater cytotoxic effects compared to those at pH 7.5. Toxicity studies in vivo showed a good tolerability to repeated administrations and furthermore, the encapsulation of the drug reduces its toxicity compared to the free compound, allowing its intravenously administration. Preliminary data show a tendency limiting tumor growth, suggesting that NCs have reached the tumor site and the drug has been released.
Conclusions
Altogether, we have developed a promising new drug delivery system based on polyurea/polyurethane nanocapsules loaded with a tambjamine analog in order to be specifically delivered in cancer cells through reductive conditions, facilitating drug transport to tumor, administration and improving drug safety.
Editorial acknowledgement
Legal entity responsible for the study
Universitat de Barcelona.
Funding
This work was partially supported by a grant from the Spanish government and the EU (PI18/00441).
Disclosure
C. Cuscó: Full / Part-time employment, Not currently employed at Ecopoltech. J. Bonelli: Full / Part-time employment: Ecopoltech. J. Rocas: Leadership role, Officer / Board of Directors: Ecopoltech. All other authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract